The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Pulmonary Veno-Occlusive Disease: Clinical, Functional, Radiologic, and Hemodynamic Characteristics and Outcome of 24 Cases Confirmed by Histology
Abstract
Pulmonary veno-occlusive disease (PVOD) is defined by specific pathologic changes of the pulmonary veins. A definite diagnosis of PVOD thus requires a lung biopsy or pathologic examination of pulmonary explants or postmortem lung samples. However, lung biopsy is hazardous in patients with severe pulmonary hypertension, and there is a need for noninvasive diagnostic tools in this patient population. Patients with PVOD may be refractory to pulmonary arterial hypertension (PAH)-specific therapy and may even deteriorate with it. It is important to identify such patients as soon as possible, because they should be treated cautiously and considered for lung transplantation if eligible. High-resolution computed tomography of the chest can suggest PVOD in the setting of pulmonary hypertension when it shows nodular ground-glass opacities, septal lines, lymph node enlargement, and pleural effusion. Similarly, occult alveolar hemorrhage found on bronchoalveolar lavage in patients with pulmonary hypertension is associated with PVOD. We conducted the current study to identify additional clinical, functional, and hemodynamic characteristics of PVOD. We retrospectively reviewed 48 cases of severe pulmonary hypertension: 24 patients with histologic evidence of PVOD and 24 randomly selected patients with idiopathic, familial, or anorexigen-associated PAH and no evidence of PVOD after meticulous lung pathologic evaluation. We compared clinical and radiologic findings, pulmonary function, and hemodynamics at presentation, as well as outcomes after the initiation of PAH therapy in both groups. Compared to PAH, PVOD was characterized by a higher male:female ratio and higher tobacco exposure (p < 0.01). Clinical presentation was similar except for a lower body mass index (p < 0.02) in patients with PVOD. At baseline, PVOD patients had significantly lower partial pressure of arterial oxygen (PaO2), diffusing lung capacity of carbon monoxide/alveolar volume (DLCO/VA), and oxygen saturation nadir during the 6-minute walk test (all p < 0.01). Hemodynamic parameters showed a lower mean systemic arterial pressure (p < 0.01) and right atrial pressure (p < 0.05), but no difference in pulmonary capillary wedge pressure. Four bone morphogenetic protein receptor II (BMPR2) mutations have been previously described in PVOD patients; in the current study we describe 2 additional cases of BMPR2 mutation in PVOD. Computed tomography of the chest revealed nodular and ground-glass opacities, septal lines, and lymph node enlargement more frequently in patients with PVOD compared with patients with PAH (all p < 0.05). Among the 16 PVOD patients who received PAH-specific therapy, 7 (43.8%) developed pulmonary edema (mostly with continuous intravenous epoprostenol, but also with oral bosentan and oral calcium channel blockers) at a median of 9 days after treatment initiation. Acute vasodilator testing with nitric oxide and clinical, functional, or hemodynamic characteristics were not predictive of the subsequent occurrence of pulmonary edema on treatment. Clinical outcomes of PVOD patients were worse than those of PAH patients. Abbreviations: BMPR2 = bone morphogenetic protein receptor II, CI = cardiac index, CT = computed tomography, DLCO = diffusing lung capacity of carbon monoxide, DLCO/VA = diffusing lung capacity of carbon monoxide/alveolar volume, FEV1 = forced expiratory volume in 1 second, HIV = human immunodeficiency virus, mPAP = mean pulmonary arterial pressure, mSAP = mean systolic arterial pressure, NO = nitric oxide, NYHA = New York Heart Association, PaCO2 = partial pressure of arterial carbon dioxide, PAH = pulmonary arterial hypertension, PaO2 = partial pressure of arterial oxygen, PCWP = pulmonary capillary wedge pressure, PVOD = pulmonary venoocclusive disease, PVRi = indexed pulmonary vascular resistance, SpO2 = pulse arterial oxygen saturation, TLC = total lung capacity, TPRi = indexed total pulmonary resistance, VC = vital capacity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ATS Statement: Guidelines for the Six-Minute Walk Test
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.166.1.at1102 · Cited by 11,195
Barst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. M., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,698
Pulmonary Arterial Hypertension in France: Results from a National Registry
Humbert, M., Sitbon, O., Chaouat, A., Bertocchi, M., Habib, G., Gressin, V., Yaici, A., Weitzenblum, E., Cordier, J.-F., Chabot, F., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200510-1668oc · Cited by 2,000
Self-citationClinical classification of pulmonary hypertension
Simonneau, G., Galiè, N., Rubin, L. J., Langleben, D., Seeger, W., Domenighetti, G., Gibbs, S., Lebrec, D., Speich, R., Beghetti, M., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.02.037 · Cited by 1,897
Self-citationPrimary Pulmonary Hypertension
Rubin, L. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701093360207 · Cited by 1,726
Treatment of Pulmonary Arterial Hypertension
Humbert, M., Sitbon, O., & Simonneau, G. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040291 · Cited by 1,707
Self-citationLong-term intravenous epoprostenol infusion in primary pulmonary hypertension
Sitbon, O., Humbert, M., Nunes, H., Parent, F., Garcia, G., Hervé, P., Rainisio, M., & Simonneau, G. É. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02012-0 · Cited by 1,383
Self-citationLong-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension
Sitbon, O., Humbert, M., Jaïs, X., Ioos, V., Hamid, A. M., Provencher, S., Garcia, G., Parent, F., Hervé, P., & Simonneau, G. (2005) · Circulation · doi:10.1161/circulationaha.104.488486 · Cited by 1,255
Self-citationAppetite-suppressant drugs and the risk of primary pulmonary hypertension
Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350901 · Cited by 1,162
Self-citationScreening, Early Detection, and Diagnosis of Pulmonary Arterial Hypertension
McGoon, M., Gutterman, D., Steen, V., Barst, R., McCrory, D. C., Fortin, T. A., & Loyd, J. E. (2004) · Chest · doi:10.1378/chest.126.1_suppl.14s · Cited by 932
Pathologic assessment of vasculopathies in pulmonary hypertension
Pietra, G. G., Capron, F., Stewart, S., Leone, O., Humbert, M., Robbins, I. M., Reid, L. M., & Tuder, R. M. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.02.033 · Cited by 709
Self-citationRubin, L. J., Mendoza, J., Hood, M., McGoon, M., Barst, R., Williams, W. B., Diehl, J. H., Crow, J., & Long, W. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-7-485 · Cited by 706
Appetite-suppressant drugs and the risk of primary pulmonary hypertension
(1997) · ACC Current Journal Review · doi:10.1016/s1062-1458(97)89579-7 · Cited by 562
Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis
Nunes, H. (2005) · Thorax · doi:10.1136/thx.2005.042838 · Cited by 420
Mutations of the TGF-β type II receptorBMPR2 in pulmonary arterial hypertension
Machado, R. D., Aldred, M. A., James, V., Harrison, R. E., Patel, B., Schwalbe, E. C., Gruenig, E., Janssen, B., Koehler, R., Seeger, W., et al. (2006) · Human Mutation · doi:10.1002/humu.20285 · Cited by 402
Self-citationDorfmüller, P., Humbert, M., Perros, F., Sanchez, O., Simonneau, G., Müller, K.-M., & Capron, F. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.11.022 · Cited by 341
Self-citationPulmonary Veno-occlusive Disease
MANDEL, J., MARK, E. J., & HALES, C. A. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.5.9912045 · Cited by 297
Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension
Provencher, S., Sitbon, O., Humbert, M., Cabrol, S., Jaïs, X., & Simonneau, G. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi728 · Cited by 296
Self-citationPaciocco, G., Martinez, F. J., Bossone, E., Pielsticker, E., Gillespie, B., & Rubenfire, M. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.17406470 · Cited by 283
Pulmonary Hypertension: CT of the Chest in Pulmonary Venoocclusive Disease
Resten, A., Maitre, S., Humbert, M., Rabiller, A., Sitbon, O., Capron, F., Simonneau, G., & Musset, D. (2004) · American Journal of Roentgenology · doi:10.2214/ajr.183.1.1830065 · Cited by 263
Self-citationGaliè, N., Seeger, W., Naeije, R., Simonneau, G., & Rubin, L. J. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.02.038 · Cited by 255
Self-citationPrimary Pulmonary Hypertension: A Histopathologic Study of 80 Cases
BJORNSSON, J., & EDWARDS, W. D. (1985) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)65277-x · Cited by 253
Severe Pulmonary Hypertension in Histiocytosis X
FARTOUKH, M., HUMBERT, M., CAPRON, F., MAÎTRE, S., PARENT, F., LE GALL, C., SITBON, O., HERVÉ, P., DUROUX, P., & SIMONNEAU, G. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.1.9807024 · Cited by 248
Self-citationLantuéjoul, S., Sheppard, M. N., Corrin, B., Burke, M. M., & Nicholson, A. G. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000209834.69972.e5 · Cited by 243
Palmer, S. M., Robinson, L. J., Wang, A., Gossage, J. R., Bashore, T., & Tapson, V. F. (1998) · Chest · doi:10.1378/chest.113.1.237 · Cited by 239
BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives
Humbert, M., Deng, Z., Simonneau, G., Barst, R. J., Sitbon, O., Wolf, M., Cuervo, N., Moore, K. J., Hodge, S. E., Knowles, J. A., et al. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.01762002 · Cited by 211
Self-citationPulmonary Veno-occlusive Disease
Holcomb Jr., B. W., Loyd, J. E., Ely, E. W., Johnson, J., & Robbins, I. M. (2000) · Chest · doi:10.1378/chest.67.4.487 · Cited by 206
HUMBERT, M., TRE, S. M., CAPRON, F., RAIN, B., MUSSET, D., & SIMONNEAU, G. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.5.9708065 · Cited by 182
Self-citationOccult alveolar haemorrhage in pulmonary veno-occlusive disease
Rabiller, A., Jaïs, X., Hamid, A., Resten, A., Parent, F., Haque, R., Capron, F., Sitbon, O., Simonneau, G., & Humbert, M. J. C. (2005) · European Respiratory Journal · doi:10.1183/09031936.06.00054105 · Cited by 146
Self-citationRISK FACTORS FOR PULMONARY ARTERIAL HYPERTENSION
Humbert, M. J. C., Nunès, H., Sitbon, O., Parent, F., Hervé, P., & Simonneau, G. (2001) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(05)70284-7 · Cited by 139
Self-citationDufour, B., Maître, S., Humbert, M. J. C., Capron, F., Simonneau, G., & Musset, D. (1998) · American Journal of Roentgenology · doi:10.2214/ajr.171.5.9798872 · Cited by 127
Self-citationPulmonary Capillary Hemangiomatosis Associated with Primary Pulmonary Hypertension
Almagro, P., Julià-Torras, J., Sanjaume, M. A. S., GONZÁLEZ, G., Casalots, J., HEREDIA, J. L., MARTÍNEZ, J., & Garau, J. (2002) · Medicine · doi:10.1097/00005792-200211000-00002 · Cited by 103
Cigarette Smoke Induces Persisting Increases of Vasoactive Mediators in Pulmonary Arteries
Wright, J. L., Tai, H., & Churg, A. (2004) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2004-0051oc · Cited by 87
Seguchi, M., Hirabayashi, N., Fujii, Y., et al. (2000) · Transplantation · doi:10.1097/00007890-200001150-00030 · Cited by 72
Vasoactive mediators and pulmonary hypertension after cigarette smoke exposure in the guinea pig
Wright, J. L., Tai, H., & Churg, A. (2005) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00274.2005 · Cited by 69
Genetics of pulmonary hypertension: from bench to bedside
Humbert, M. J. C., & Trembath, R. C. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.02702002 · Cited by 64
Self-citationPulmonary veno-occlusive disease in siblings: Case reports and morphometric study
Davies, P. A., & REID, L. M. (1982) · Human Pathology · doi:10.1016/s0046-8177(82)80051-8 · Cited by 64
Familial pulmonary veno-occlusive disease: a case report.
Voordes, C. G., Kuipers, J., & Elema, J. D. (1977) · Thorax · doi:10.1136/thx.32.6.763 · Cited by 61
Pulmonary veno‐occlusive disease in pulmonary Langerhans′ cell granulomatosis
Hamada, K., Teramoto, S., Narita, N., et al. (2000) · European Respiratory Journal · doi:10.1034/j.1399-3003.2000.15b33.x · Cited by 60
Pulmonary veno-occlusive disease in a HIV-infected intravenous drug abuser
Escamilla, R., Hermant, C., Berjaud, J., Mazerolles, C., & Daussy, X. (1995) · European Respiratory Journal · doi:10.1183/09031936.95.08111982 · Cited by 56
Ed, R., Nojadera, G., Rutstein, R. M., & Rudy, B. (1994) · PubMed · Cited by 54
Effects of inhaled nitric oxide and aerosolized iloprost in pulmonary veno-occlusive disease
Hoeper, M. M., Eschenbruch, C., Zink-Wohlfart, C., et al. (1999) · Respiratory Medicine · doi:10.1016/s0954-6111(99)90079-3 · Cited by 33
Cited by
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Self-citationUpdated clinical classification of pulmonary hypertension
Simonneau, G., Gatzoulis, M. A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Gomez Sanchez, M. A., Krishna Kumar, R., Landzberg, M., Machado, R. F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.029 · Cited by 4,191
Self-citationHaemodynamic definitions and updated clinical classification of pulmonary hypertension
Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., Krowka, M., Williams, P. G., & Souza, R. (2019) · European Respiratory Journal · doi:10.1183/13993003.01913-2018 · Cited by 3,813
Self-citationGaliè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01032-2015 · Cited by 3,172
Self-citationUpdated Clinical Classification of Pulmonary Hypertension
Simonneau, G., Robbins, I. M., Beghetti, M., Channick, R. N., Delcroix, M., Denton, C. P., Elliott, C. G., Gaine, S. P., Gladwin, M. T., Jing, Z.-C., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.012 · Cited by 2,093
Self-citation
Metadata
- Authors
- Montani, D., Achouh, L., Dorfmüller, P., Le Pavec, J., Sztrymf, B., Tchérakian, C., Rabiller, A., Haque, R., Sitbon, O., Jaïs, X., Dartevelle, P., Maître, S., Capron, F., Musset, D., Simonneau, G., & Humbert, M.
- Venue
- Medicine
- Published
- 2008-07
- Volume
- 87
- Issue
- 4
- Pages
- 220-233
- ISSN
- 0025-7974 (ISSN-L)
- OpenAlex
- W1978752282
- Cited by
- 355
- References
- 42
- FWCI
- 15.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.